I guess there us room for some CD3xYYY bispecific, but am not sure that DART is right choice??? Roche is leading here, I think. REGN is trying (and some others), but tox profile continut to be problem
For DART, complex continuous iv-dosing, and than that toxicity.....
MGD006 may just follow CD3xCD19 path. :-(
My bets are on bispecific antiPD1xLAG3 (from the animal preclinical results), but this is still DART.... with improved profile, so every 3W dosing at 10-15 mg/Kg ....well, just may be right molecule.